Comparing Everolimus to Sunitinib in Non-clear-cell Renal Cell Carcinoma

Affiliations

¹ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
² Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. Electronic address: borje.ljungberg@urologi.umu.se.

Editorial

Axel Bex et al. Eur Urol. 2016 May.

. 2016 May;69(5):875-6.

doi: 10.1016/j.eururo.2015.11.013. Epub 2015 Nov 26.

¹ Department of Urology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
² Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden. Electronic address: borje.ljungberg@urologi.umu.se.

No abstract available

Comment on

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.
Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, Rao P, Sircar K, Karam JA, McDermott DF, Wood CG, Choueiri TK. Tannir NM, et al. Eur Urol. 2016 May;69(5):866-74. doi: 10.1016/j.eururo.2015.10.049. Epub 2015 Nov 26. Eur Urol. 2016. PMID: 26626617 Free PMC article. Clinical Trial.